Filing search / Alkermes plc / "Commitment" / Page 3

DEFA14A

g1qokoomv0jtgw 22z42

16 Feb 22

Additional proxy soliciting materials

7:17am

8-K

EX-99.1

wby den0yiqe4sfe

16 Feb 22

Results of Operations and Financial Condition

7:05am

8-K

EX-99.2

wkxbds

16 Feb 22

Results of Operations and Financial Condition

7:05am

DEFA14A

EX-99.2

aavfa9gmrduczy1j1

11 Jan 22

Additional proxy soliciting materials

7:02am

DEFA14A

EX-99.1

gpd5naxoirontw5njg

11 Jan 22

Additional proxy soliciting materials

7:02am

8-K

EX-99.1

ytwv6v5h kk21

11 Jan 22

Regulation FD Disclosure

7:00am

8-K

EX-99.2

t5dmx

11 Jan 22

Regulation FD Disclosure

7:00am

8-K

EX-99.1

w8fu41 nj

1 Jun 21

Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder

7:09am

DEFA14A

EX-99.1

qqvdk82ve55l

20 May 21

Additional proxy soliciting materials

7:11am

8-K

EX-99.1

zr1a5

20 May 21

Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors

7:10am

DEFA14A

EX-99.1

8d2ybemakjz gtop

30 Apr 21

Additional proxy soliciting materials

7:11am

8-K

EX-99.1

1rjug9as8vgz

30 Apr 21

Alkermes Announces Agreement with Sarissa Capital

7:10am

8-K

EX-99.1

qyhxh7p81

25 Mar 21

Regulation FD Disclosure

12:00am